KDM6B Antibody

1. The KDM6B inhibitor GSK-J4 perturbed the PMA-mediated differentiation of THP-1 cells. The AURKA inhibitor alisertib accelerates the expression of the H3K27 demethylase KDM6B, dissociating AURKA and YY1 from the KDM6B promoter region and inducing differentiation. PMID: 29477140
2. The interaction of methyltransferase EZH2 or demethylase JMJD3 on RGMA, RARb2, AR, PGR, and ERa genes in the progression and aggressiveness of prostate cancer. PMID: 29161520
3. We demonstrate that extraskeletal osteosarcoma (ESOS) may include at least two small subsets: an MDM2-amplified deep soft-tissue ESOS and an H3K27me3-deficient organ-based ESOS PMID: 29489027
4. Our results demonstrate that in the early stage of sepsis, JMJD3 contributes to high levels of neutrophil mPR3 expression and thereby to the production of the inflammatory cytokine IL-1beta PMID: 29621735
5. Computational methods identifyied H3(17-33)-derived peptides with improved binding affinity that would allow co-crystallization with the KDM6B catalytic core. A co-crystallized H3(17-33)A21M peptide had interactions between the KDM6B zinc binding domain and the H3(17-23) region. KDM6B uses the zinc binding domain to achieve H3K27me3/me2 specificity. A 1564 His-to-Gln substitution explains its higher affinity than KDM6A. PMID: 29220567
6. Taken together, the authors propose that the miR-939-Jmjd3 axis perturbs the accessibility of hepatitis B virus enhancer II/core promoter (En II) promoter to essential nuclear factors (C/EBPalpha and SWI/SNF complex) therefore leading to compromised viral RNA synthesis and hence restricted viral multiplication. PMID: 27779233
7. These results demonstrated that histone demethylase JMJD3 regulates CD11a expression in lupus T cells by affecting the H3K27me3 levels in the ITGAL (CD11a) promoter region, and JMJD3 might thereby serve as a potential therapeutic target for SLE. PMID: 28430662
8. binding of SMAD2/3, the intracellular effectors of activin signaling, was significantly enriched at the Pmepa1 gene, which encodes a negative feedback regulator of TGF-beta signaling in cancer cells, and at the Kdm6b gene, which encodes an epigenetic regulator promoting transcriptional plasticity. PMID: 26215835
9. In this study, we showed that aberrantly upregulated JMJD3 exerts an anti-apoptotic effect in diffuse large B-cell lymphoma PMID: 27102442
10. Our study therefore delineates KDM6B function that links NF-kappaB and MAPK signaling pathway mediating MM cell growth and survival, and validates KDM6B as a novel therapeutic target in MM. PMID: 28487543
11. Here, we discuss the roles of lysine 27 demethylases, JMJD3 and UTX, in cancer and potential therapeutic avenues targeting these enzymes. Despite a high degree of sequence similarity in the catalytic domain between JMJD3 and UTX, numerous studies revealed surprisingly contrasting roles in cellular reprogramming and cancer, particularly leukemia PMID: 27151432
12. inhibition of the H3K27 demethylase JMJD3 in naive CD4 T cells demonstrates how critically important molecules required for T cell differentiation, such as JAK2 and IL12RB2, are regulated by H3K27me3. PMID: 28947543
13. KDM6B expression strongly correlates with ERbeta level in human pleural mesothelioma tumors and cell lines. PMID: 27529370
14. Low JMJD3 expression is associated with breast cancer. PMID: 28423536
15. Transient and forced expression of JMJD3c followed by the forced expression of lineage-defining transcription factors enabled the hPSCs to activate tissue-specific genes directly. Study have also shown that the introduction of JMJD3c facilitates the differentiation of hPSCs into functional hepatic cells and skeletal muscle cells. PMID: 27802135
16. results demonstrate that the regulation of Jmjd3 by STAT3 maintains repression of differentiation specific genes and is therefore important for the maintenance of self-renewal of normal neural and glioblastoma stem cells PMID: 28384648
17. Data show that histone demethylase JMJD3 was reduced and its target gene Snai1 expression was down-regulated after HOTAIR suppression. PMID: 28177890
18. The number of Kdm6b-positive chondrocytes was lower in human osteoarthritis cartilage samples. PMID: 28314754
19. Kdm6a and Kdm6b were found to be significantly overexpressed in Malignant pleural mesothelioma (MPM) at the mRNA level. However, tests examining if targeting therapeutically Kdm6a/b using a specific small molecule inhibitor was potentially useful for treating MPM, revealed that members of the Kdm6 family may not be suitable candidates for therapy PMID: 28197626
20. Lipopolysaccharide treatment recruited Jmjd3 and NF-kappaB to the promoter region of target genes, suggesting Jmjd3 synergizes with NF-kappaB to activate the expression of target genes. PMID: 28189690
21. Incubation of nickel chloride upregulated the expression of H3K27me3 demethylase jumonji domain-containing protein 3 (JMJD3) in kidney cancer cells, which was accompanied by the reduction in the protein level of H3K27me3. Enhanced demethylation of H3K27me3 may represent a novel mechanism underlying the carcinogenicity of nickel compounds. PMID: 25427687
22. JMJD3 gene expression in renal cell carcinoma and bladder cancer. PMID: 27983522
23. JMJD3 and EZH2 in prostate biopsies also demonstrated an increase of JMJD3 and EZH2 in adenocarcinoma with Gleason score 7 and 8 by comparison with a normal biopsy. PMID: 26871869
24. Low JMJD3 expression is associated with Colorectal Cancer. PMID: 26416711
25. JMJD3 up-regulation and NF-kappaB activation occur in the region of the wound edge during keratinocyte wound healing PMID: 26802933
26. JMJD3 promotes SAHF formation by demethylating RB at K810, which reduce the level of phosphorylation of RB protein at S807/811, and this interplay promotes the formation of senescence-associated heterochromatin foci in senescent WI38 cells. PMID: 25698448
27. We demonstrate that KDM6B plays a key role in clear cell renal cell carcinoma PMID: 26261509
28. Findings reveal a novel epigenetic mechanism by which JMJD3 promotes melanoma progression and metastasis. PMID: 26729791
29. JMJD3 is an epigenetic regulator in development and disease. (Review) PMID: 26193001
30. KDM6B may act in a pro-apoptotic role in NSCLC. PMID: 26303949
31. Demethylation of IGFBP5 by Histone Demethylase KDM6B Promotes Mesenchymal Stem Cell-Mediated Periodontal Tissue Regeneration by Enhancing Osteogenic Differentiation and Anti-Inflammation Potentials. PMID: 25827480
32. Data indicate a reverse correlation between the mRNA levels of histone H3 lysine-27 demethylase (JMJD3) and global histone h3 lysine 27 methylation (H3K27me3). PMID: 25791244
33. Results show that JMJD3 protein is overexpressed in high-grade glioma cells and correlated with dysfunctional activation of senescence-related processes, including proinflammatory cytokines and stem cell tropism toward tumors. PMID: 25652587
34. KDM6B is a new hypoxia response gene regulated by HIF-2alpha PMID: 25520177
35. Subcellular localization of Jmjd3 is dynamically regulated and has pivotal roles for H3K27me3 status. PMID: 24646476
36. JMJD3 is recruited to p53 responsive elements via its interaction with p53 and therefore could act as a fail-safe mechanism to remove low levels of H3K27me3 and H3K27me2 to allow for efficient acetylation of H3K27. PMID: 24797517
37. JMJD3 at the nexus of epigenetic regulation of inflammation and the aging process PMID: 24925089
38. our results propose a significant role for the KDM6B-C/EBPalpha axis in the pancreatic ductal adenocarcinoma phenotype. PMID: 24947179
39. demonstrated that miR-941 and KDM6B regulated the epithelial-mesenchymal transition process and affected cell migratory/invasive properties PMID: 25049231
40. Studies indicate that Jmjd3 is able to enhance the polarization of M2 microglia by modifying histone H3K27me3, and it has a pivotal role in the switch of microglia phenotypes that may contribute to the immune pathogenesis of PD. PMID: 24212761
41. JMJD3 promotes osteogenesis in differentiating human mesenchymal stem cells, with MIR146A regulating JMJD3. PMID: 24726732
42. Histone demethylase Jmjd3 is required for the development of subsets of retinal bipolar cells. PMID: 24572572
43. results demonstrated critical role of histone demethylase in epigenetic regulation of odontogenic differentiation of dental MSCs. KDM6B may present potential therapeutic target in regeneration of tooth structures and repair of craniofacial defects. PMID: 24158144
44. Overexpression of JMJD3 is associated with myelodysplastic syndrome. PMID: 23538751
45. Data suggest that the suppression of different key inflammatory regulators through JMJD3-attenuation would evaluate potential therapeutic targets and to elucidate the molecular mechanism of JMJD3-knockdown (KD) dependent effects in THP-1 cells. PMID: 23711388
46. KDM6B contributes to the activation of WNT3 and DKK1 at different differentiation stages when WNT3 and DKK1 are required for mesendoderm and definitive endoderm differentiation. PMID: 22907667
47. Deregulation of JMJD3 may contribute to gliomagenesis via inhibition of the p53 pathway resulting in a block to terminal differentiation. PMID: 23236496
48. These data demonstrate a novel role of H3 Lys27 histone methylation in fibrosis in systemic sclerosis. PMID: 22915621
49. Overexpression of KDM6B induced the expression of mesenchymal genes and promoted epithelial-mesenchymal transition. PMID: 23152497
50. ATF4-dependent regulation of the JMJD3 gene during amino acid deprivation can be rescued in Atf4-deficient cells by inhibition of deacetylation. PMID: 22955275

Show More

Hide All

HGNC: 29012

OMIM: 611577

KEGG: hsa:23135

STRING: 9606.ENSP00000254846

UniGene: Hs.223678